Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breathing-Guided radiation aims to protect healthy lung tissue

NCT ID NCT02843568

Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study investigates whether 4DCT scans—which capture how a tumor moves when a person breathes—can be used to design radiation plans that avoid high-functioning healthy lung tissue. People with non-small cell lung cancer who are scheduled for radiation therapy may join. The goal is to preserve lung function by targeting the tumor while minimizing damage to surrounding healthy areas.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiation therapy (standard fractionation or stereotactic body radiation therapy)
What this could lead to
If successful, this approach could help preserve lung function in people receiving radiation for lung cancer, potentially improving quality of life.
What could go wrong
This is an early-stage study focused on imaging and planning techniques, not a new treatment. It may not lead to better outcomes or be widely adoptable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

122 people

The number who actually took part.

Started

Aug 2016

Finished

Aug 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologic diagnosis of non-small cell lung cancer or lung metastasis from a solid tumor. One biopsy site is adequate for multiple sites of thoracic disease. * Treatment includes localized radiation therapy with or without chemotherapy * Karnofsky ≥ 60% * Not pregnant per radiation oncology standard procedures * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Prior (within last 6 months) or future planned therapeutic surgery for the treatment of the existing lung cancer * Prior thoracic radiotherapy * Severe COPD defined as disease requiring an inpatient stay for respiratory deterioration within the past 3 months * Oxygen dependence of \> 2 L/min continuously throughout the day at baseline * Known underlying collagen vascular disease or intrinsic lung disease that could complicate expected sequelae of radiation (idiopathic pulmonary fibrosis, Wegener's granulomatosis) * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung metastasis from A solid tumor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non small cell lung cancer

Contacts and locations

Locations

  • UW Johnson Creek

    Johnson Creek, Wisconsin, 53038, United States

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.